The European Innovation Council (EIC) is showcasing some of its best companies developing solutions to tackle Cardiovascular and Respiratory Diseases. The ePitching session will take place on 15 February at 13:00 CET. Join this online event to connect with top EIC innovators and explore new investment opportunities!
Are you an investor with a history in the Healthcare sector and a particular focus on solutions to tackle cardiovascular or respiratory diseases?
If so, the EIC ePitching on Cardiovascular and Respiratory Diseases is your chance to get to know some of the top EIC-funded projects breaking ground in these niches. This is your opportunity to hear from a curated list of pitching companies, with the option of scheduling virtual one-on-one meetings after the session.
Interested? Join us on 15 February 2024, at 13:00 CET and start connecting with some of the best EIC innovators.
Sign up for the event
Applications are open until 14 February.
Who can join?
The EIC is looking for Venture Capitalists, Corporate VCs, Family Offices or Angel Investors with a history of backing solutions to tackle Cardiovascular and Respiratory Diseases.
Which companies will participate?
The pitching companies will be selected by a jury panel with investors from Amadeus Capital Partners, Apollo Health Venture, BioGeneration Ventures, Bionova Capital, Böhringer Ingelheim Venture Fund, Bullnet Capital, Capricorn Partners, Eleven Ventures, Hadean Ventures, High-Tech Gründerfonds, Indaco Venture Partners, Invivo Capital, Karista Ventures, Kurma Partners, MIG AG, Novo Holdings, Panakès Partners, Pathena Investments, Peppermint Venture Partners, Supernova Invest, Turenne Capital, V-Bio Ventures, Vesalius Biocapital, Ventura Biomed, Xange, Ysios Capital.
You can find the preliminary list of participating companies below:
AdjuCor is a high-tech medical device company that owns and is responsible for the development, production, marketing and selling of disruptive platform technology for the treatment of patients with advanced heart failure (HF), namely reBEAT.
AMT Medical has developed a cardiovascular device for minimal invasive coronary bypass surgery. Based on the same technology, the experienced team has already developed a similar device for neurosurgery and brought this successfully to the market in the US and Europe, saving lives of thousands brain patients. In 2017-2019, AMT Medical finished the preclinical product design and development, which were successfully proven in in vivo PoC and validation studies in a porcine bypass model.
Aortyx designs and develops a new generation of biocompatible and bioabsorbable patches to treat aortic diseases. The patches are implanted using a specifically designed endovascular catheter. Aortyx patches mimic the mechanical properties of the intervened tissue, facilitating its regeneration and guaranteeing superior surgical outcomes compared to those achieved with currently used devices.
Healium Medical focuses on significantly simplifying the rapid growing market of ablation procedures with advanced miniaturized ultrasound guided therapeutic technology. Their technology, Dual-Mode Ultrasound Technology (DMUT) is intended for non-contact, continuous ablation therapy with real-time tissue monitoring. DMUT delivers precise ultrasonic energy for safe and rapid lesion placement via miniature transcatheter ultrasound technology and advanced signal and image processing.
Nimble Diagnostics is developing the first medical device to monitor patients with implanted stents non invasively, independent of stent type or location, in less than 5 seconds and thus facilitating preventive care and eliminating the need for confirmatory surgery, X-ray radiation and hospitalization for millions of patients.
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels and valves. Xeltis’ devices seek to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient’s own tissue within and around it, before gradually being absorbed and leaving new, living and long-lasting vessels and valves in place.
About the EIC Ecosystem Partnerships and Co-Investment Support Programme
The Ecosystem Partnerships and Co-Investment Support Programme is expanding the EIC’s Business Acceleration Services (BAS) by creating a network of specialized, sector-focused partners that can help innovators access the services they need. It is also dedicated to promoting co-investment along with the EIC Fund, by preparing beneficiaries to interact with investors and connecting them through matchmaking and dedicated events.
Should you have any questions regarding the event, please contact us through the email: investments@eicfund.eu.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.